Clinical trial

QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk TNBC Breast Cancer

NCT06404736

Drugs and interventions used in this trial

3 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention Bispecific antibody (bsAb) targeting PD-1 and CLTA-4 Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Albumin-bound paclitaxel Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Carboplatin Normalized identity: carboplatinView linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk TNBC Breast Cancer

Design: INTERVENTIONAL · Status: NOT YET RECRUITING · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusNOT_YET_RECRUITING

Study typeINTERVENTIONAL

Start date2024-05-07

PhasePHASE2

Conditions

Early Breast Cancerunresolved

Neoadjuvant Therapyunresolved

TNBC, Triple Negative Breast Cancerunresolved

Interventions

Bispecific antibody (bsAb) targeting PD-1 and CLTA-4DRUG

Albumin-bound paclitaxelDRUG

CarboplatinDRUG · verified · RxNorm: carboplatin

Sponsors & collaborators

Fudan Universitylead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06404736 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.